The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States
Open accessAbstract
Candida bloodstream isolates ( n = 2,000) from two multicenter clinical trials carried out by the National Institute of Allergy and Infectious Diseases Mycoses Study Group between 1995 and 1999 were tested against amphotericin B (AMB), flucytosine (5FC), fluconazole (FLU), itraconazole (ITR), voriconazole (VOR), posaconazole (POS), caspofungin (CFG), micafungin (MFG), and anidulafungin (AFG) using the NCCLS M27-A2 microdilution method. All drugs were tested in the NCCLS-specified RPMI 1640 medium except for AMB, which was tested in antibiotic medium 3. A sample of isolates was also tested in RPMI 1640 supplemented to 2% glucose and by using the diluent polyethylene glycol (PEG) in lieu of dimethyl sulfoxide for those drugs insoluble in water. Glucose supplementation tended to elevate the MIC, whereas using PEG tended to decrease the MIC. Trailing growth occurred frequently with azoles. Isolates were generally susceptible to AMB, 5FC, and FLU. Rates of resistance to ITR approached 20%. Although no established interpretative breakpoints are available for the candins (CFG, MFG, and AFG) and the new azoles (VOR and POS), they all exhibited excellent antifungal activity, even for those strains resistant to the other aforementioned agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
National Committee for Clinical Laboratory Standards
Bruck, E. (1980) · Pediatrics · doi:10.1542/peds.65.1.187 · Cited by 14,751
Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis
Mora-Duarte, J., Betts, R., Rotstein, C., Colombo, A. L., Thompson-Moya, L., Smietana, J., Lupinacci, R., Sable, C., Kartsonis, N., & Perfect, J. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021585 · Cited by 1,380
Practice Guidelines for the Treatment of Candidiasis
Rex, J. H., Walsh, T. J., Sobel, J. D., Filler, S. G., Pappas, P. G., Dismukes, W. E., & Edwards, J. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313749 · Cited by 927
Self-citationRex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citationEpidemiology of Nosocomial Fungal Infections, with Emphasis on Candida Species
Jarvis, W. R. (1995) · Clinical Infectious Diseases · doi:10.1093/clinids/20.6.1526 · Cited by 636
Rex, J. H., Pappas, P. G., Karchmer, A. W., Sobel, J., Edwards, J. E., Hadley, S., Brass, C., Vazquez, J. A., Chapman, S. W., Horowitz, H. W., et al. (2003) · Clinical Infectious Diseases · doi:10.1086/374850 · Cited by 495
Self-citationResistance Mechanisms in Clinical Isolates of Candida albicans
White, T. C., Holleman, S., Dy, F., Mirels, L. F., & Stevens, D. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1704-1713.2002 · Cited by 461
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
Self-citationPfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., Hollis, R. J., & The SENTRY Participant Group (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.3.747-751.2000 · Cited by 378
Has antifungal susceptibility testing come of age
Rex, J. H., & Pfaller, M. A. (2002) · Clinical Infectious Diseases · doi:10.1086/342384 · Cited by 361 · cited 2×
“The nature of the trailing phenomenon is unknown, as is its contribution to the perception of resistance in vitro and the ultimate possibility of in vivo resistance translation (14, 31, 33, 36, 42).”
BackgroundSelf-citationAntifungal susceptibility testing
Rex, J. H., Pfaller, M. A., Rinaldi, M. G., Polak, A., & Galgiani, J. N. (1993) · Clinical Microbiology Reviews · doi:10.1128/cmr.6.4.367 · Cited by 361
Self-citationAlly, R., Schürmann, D., Kreisel, W., Carosi, G., Aguirrebengoa, K., Dupont, B., Hodges, M., Troke, P., Romero, A. J., & the Esophageal Candidiasis Study Group (2001) · Clinical Infectious Diseases · doi:10.1086/322653 · Cited by 331 · cited 1×
“Early in vivo and clinical experiences against infections caused by these organisms are encouraging as well (1, 9, 19, 27, 38).”
BackgroundPfaller, M. A., Jones, R. N., Doern, G. V., Sader, H. S., Hollis, R. J., Messer, S. A., & Group, F. T. S. P. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.7.1886-1889.1998 · Cited by 281
Pfaller, M. A., Jones, R. N., Doern, G. V., Fluit, A. C., Verhoef, J., Sader, H. S., Messer, S. A., Houston, A., Coffman, S., & Hollis, R. J. (1999) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(99)00046-2 · Cited by 264
Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., & Diekema, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.6.1723-1727.2002 · Cited by 232
Pfaller, M. A., Diekema, D. J., Messer, S. A., Hollis, R. J., & Jones, R. N. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.3.1068-1071.2003 · Cited by 166
Epidemiology of opportunistic invasive mycoses.
Kullberg, B. J., & Lashof, A. M. L. O. (2002) · PubMed · Cited by 159
Arthington-Skaggs, B. A., Lee-Yang, W., Ciblak, M. A., Frade, J. P., Brandt, M. E., Hajjeh, R. A., Harrison, L. H., Sofair, A. N., & Warnock, A. D. W. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.8.2477-2481.2002 · Cited by 158
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2862-2864.2001 · Cited by 146
The Trailing End Point Phenotype in Antifungal Susceptibility Testing Is pH Dependent
Marr, K. A., Rustad, T. R., Rex, J. H., & White, T. C. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.6.1383 · Cited by 145
Self-citationRevankar, S. G., Kirkpatrick, W. R., McAtee, R. K., Fothergill, A. W., Redding, S. W., Rinaldi, M. G., & Patterson, T. F. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.1.153-156.1998 · Cited by 133 · cited 2×
“The nature of the trailing phenomenon is unknown, as is its contribution to the perception of resistance in vitro and the ultimate possibility of in vivo resistance translation (14, 31, 33, 36, 42).”
BackgroundNovel triazole antifungal agents
Hoffman, H. L., Ernst, E. J., & Klepser, M. E. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.3.593 · Cited by 133
Pfaller, M. A., Messer, S. A., Boyken, L., Huynh, H., Hollis, R. J., & Diekema, D. J. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.11.3518-3521.2002 · Cited by 132
Pfaller, M. A., Bale, M. J., Buschelman, B. J., Lancaster, M., Espinel-Ingroff, A. V., Rex, J. H., Rinaldi, M. G., Cooper, C. R., & McGinnis, M. R. (1995) · Journal of Clinical Microbiology · doi:10.1128/jcm.33.5.1104-1107.1995 · Cited by 127
Self-citationRuhnke, M., Schmidt‐Westhausen, A. M., & Trautmann, M. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.3.575 · Cited by 126
Antifungal Susceptibility Testing: Technical Advances and Potential Clinical Applications
Pfaller, M. A., Rex, J. H., & Rinaldi, M. G. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.5.776 · Cited by 123
Self-citationPfaller, M. A., Messer, S. A., Boyken, L. B., Tendolkar, S., Hollis, R. J., & Diekema, D. J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.5.2176-2179.2003 · Cited by 86
Standardization of antifungal susceptibility testing and clinical relevance.
Espinel-Ingroff, A. V., Barchiesi, F., Hazen, K. C., Martı́nez-Suárez, J. V., & Scalise, G. (1998) · PubMed · Cited by 82
Glucan synthase inhibitors as antifungal agents
Kurtz, M. B., & Rex, J. H. (2001) · Advances in protein chemistry · doi:10.1016/s0065-3233(01)56011-8 · Cited by 79
Self-citationANTIFUNGAL SUSCEPTIBILITY TESTING
Pfaller, M. A., & Yu, W. L. (2001) · Infectious Disease Clinics of North America · doi:10.1016/s0891-5520(05)70192-6 · Cited by 77
Vazquez, J. A., Peng, G., Sobel, J. D., Steele‐Moore, L., Schuman, P., Holloway, W., Neaton, J. D., & (CPCRA), T. T. B. C. P. F. C. R. O. A. (2001) · Clinical Infectious Diseases · doi:10.1086/322641 · Cited by 57
Rex, J. H., Pfaller, M. A., Lancaster, M., Odds, F. C., Bolmström, A., & Rinaldi, M. G. (1996) · Journal of Clinical Microbiology · doi:10.1128/jcm.34.4.816-817.1996 · Cited by 47
Self-citationGhannoum, M. A., Okogbule-Wonodi, I., Bhat, N., & Sanati, H. (1999) · Journal of Chemotherapy · doi:10.1179/joc.1999.11.1.34 · Cited by 42
McClenny, N. B., Fei, H., Baron, E. J., Gales, A. C., Houston, A., Hollis, R. J., & Pfaller, M. A. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.5.1325-1328.2002 · Cited by 39
In Vitro Antifungal Susceptibility Testing
Hoffman, H. L., & Pfaller, M. A. (2001) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.21.12.111s.34510 · Cited by 37
Cuenca‐Estrella, M., & Rodríguez-Tudela, J. L. (2001) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2001.tb00009.x · Cited by 35
Role of Newer Azoles in Surgical Patients
Patterson, T. F. (1999) · Journal of Chemotherapy · doi:10.1179/joc.1999.11.6.504 · Cited by 33
Susceptibility Testing of Fungi and Correlation with Clinical Outcome
Ghannoum, M. A. (1997) · Journal of Chemotherapy · doi:10.1080/1120009x.1997.12113186 · Cited by 32
Resistance to antifungal agents in the critical care setting: problems and perspectives.
Martins, & Rex, J. H. (1996) · PubMed · Cited by 30
Self-citationEvaluation of a Method for Identification of Candida dubliniensis Bloodstream Isolates
Sancak, B., Rex, J. H., Paetznick, V. L., Chen, E., & Rodriguez, J. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.1.489-491.2003 · Cited by 24
Self-citationParadoxical effect of antibiotics: I. The‘Eagle effect’
SHAH, P. M. (1982) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/10.4.259 · Cited by 23
Is Antifungal Susceptibility Testing Useful in Guiding Fluconazole Therapy?
Ghannoum, M. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.supplement_2.s161 · Cited by 20
St‐Germain, G. (1990) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.34.12.2304 · Cited by 20
Cited by
Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Candida parapsilosis, an Emerging Fungal Pathogen
Trofa, D., Gácser, A., & Nosanchuk, J. D. (2008) · Clinical Microbiology Reviews · doi:10.1128/cmr.00013-08 · Cited by 854
Pfaller, M. A., & Diekema, D. J. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.10.4419-4431.2004 · Cited by 694
Kuse, E.-R., Chetchotisakd, P., da Cunha, C. A., Ruhnke, M., Barrios, C., Raghunadharao, D., Sekhon, J. S., Freire, A., Ramasubramanian, V., Demeyer, I., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60605-9 · Cited by 692
Self-citation
Metadata
- Authors
- Ostrosky-Zeichner, L., Rex, J. H., Pappas, P. G., Hamill, R. J., Larsen, R. A., Horowitz, H. W., Powderly, W. G., Hyslop, N., Kauffman, C. A., Cleary, J., Mangino, J. E., & Lee, J.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2003-10
- Volume
- 47
- Issue
- 10
- Pages
- 3149-3154
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2158530375
- Cited by
- 498
- References
- 44
- FWCI
- 26.71
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.